Announcements
- Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
- Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
- Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
- Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼
Key statistics
On Tuesday, Beam Therapeutics Inc (BEAM*:MEX) closed at 401.10, 0.00% above its 52-week low of 401.10, set on Jan 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 401.10 |
Low | 401.10 |
Bid | -- |
Offer | -- |
Previous close | 425.82 |
Average volume | 0.00 |
---|---|
Shares outstanding | 82.31m |
Free float | 81.12m |
P/E (TTM) | -- |
Market cap | 1.90bn USD |
EPS (TTM) | -1.74 USD |
Data delayed at least 20 minutes, as of Jan 30 2024 11:30 GMT.
More ▼